Guardion Health Sciences Inc (GHSI) Sector
Health Care

(Current) $3.23
-0.04 (-1.22%) Open Price: 3.22

 

Guardion Health Sciences Inc. is a healthcare company founded in 2009 and headquartered in San Diego, California. The company focuses on the development and commercialization of products to diagnose, treat, and manage ocular diseases and other chronic diseases related to aging. Guardion's flagship product, Lumega-Z, is a medical food product designed to improve visual performance in patients with macular degeneration and other ocular diseases.

 

Guardion Health Sciences operates in two business segments: (1) medical foods and supplements and (2) medical devices and testing services. The medical foods and supplements segment offers Lumega-Z, a medical food product designed to address specific nutritional deficiencies in patients with macular degeneration and other ocular diseases. The medical devices and testing services segment offers diagnostic tests and medical devices designed to diagnose and manage macular degeneration and other ocular diseases.

 

In May 2019, Guardion Health Sciences completed its initial public offering (IPO) and began trading on the NASDAQ Capital Market under the symbol "GHSI". The company raised approximately $6.5 million in net proceeds from the offering, which it planned to use to support product development and commercialization efforts.

 

Guardion Health Sciences has partnerships with several healthcare companies and organizations, including the National Eye Institute, the American Society of Retina Specialists, and the Macular Degeneration Association. These partnerships allow the company to collaborate on research and development efforts, as well as increase awareness of ocular diseases and related treatments.

 

Guardion Health Sciences is led by CEO Michael Favish, who has extensive experience in the healthcare industry. Prior to joining Guardion, Favish held leadership positions at several healthcare companies, including OptumHealth and UnitedHealth Group. Under his leadership, Guardion Health Sciences has continued to focus on the development and commercialization of innovative products to diagnose and treat ocular diseases and other chronic diseases related to aging.

 



 

(10/30/24) $3.22
(10/14/24) $3.27
(10/14/24) (Qty.)91,680
(10/30/24) $3.22
(10/30/24) $3.29
(10/13/24) $3.17
(10/06/24) $3.40
Stocktwits
LetsEncrypt SSL Secure Stripe Payment Processing